The PDGF-D/miR-106a/Twist1 Pathway Orchestrates Epithelial-Mesenchymal Transition in Gemcitabine Resistance Hepatoma Cells.

Rui Wang,Yumei Li,Yueyue Hou,Qingling Yang,Sulian Chen,Xi Wang,Zishu Wang,Yan Yang,Changjie Chen,Zhiwei Wang,Qiong Wu

DOI: https://doi.org/10.18632/oncotarget.3193

2015-01-01

Oncotarget

Abstract:Emerging evidence demonstrates that platelet-derived growth factor-D (PDGF-D) plays a critical role in epithelial-mesenchymal transition (EMT) and drug resistance in hepatocellular carcinoma (HCC) cells. However, the underlying mechanism has not been fully elucidated. The objective is to explore the molecular mechanism of PDGF-D-mediated EMT in drug resistance HCC cells. To achieve our goal, we used multiple approaches including Western blotting, real-time RT-PCR, wound healing assay, invasion assay, luciferase activity assay, transfection, and immunohistochemistry. We found that PDGF-D is highly expressed in gemcitabine-resistant (GR) HCC cells. Moreover, PDGF-D markedly inhibited miR-106a expression and subsequently upregulated Twist1 expression. Notably, PDGF-D expression was associated with miR-106a and Twist1 in HCC patients. Our findings provide a possible molecular mechanism for understanding GR chemoresistance in HCC cells. Therefore, inactivation of PDGF-D/Twist or activation of miR-106a could be a novel strategy for the treatment of HCC.